KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Enterprise Value (2019 - 2025)

Historic Enterprise Value for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $2.3 billion.

  • Royalty Pharma's Enterprise Value fell 579.77% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 579.77%. This contributed to the annual value of $2.4 billion for FY2024, which is 2135.27% down from last year.
  • Latest data reveals that Royalty Pharma reported Enterprise Value of $2.3 billion as of Q3 2025, which was down 579.77% from $2.5 billion recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Enterprise Value peaked at $4.2 billion during Q1 2021, and registered a low of $1.4 billion during Q2 2023.
  • Its 5-year average for Enterprise Value is $2.5 billion, with a median of $2.5 billion in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 460354.39% in 2021, then tumbled by 4483.2% in 2022.
  • Quarter analysis of 5 years shows Royalty Pharma's Enterprise Value stood at $2.9 billion in 2021, then fell by 23.73% to $2.2 billion in 2022, then skyrocketed by 40.15% to $3.1 billion in 2023, then fell by 21.35% to $2.4 billion in 2024, then decreased by 6.52% to $2.3 billion in 2025.
  • Its Enterprise Value stands at $2.3 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.0 billion for Q1 2025.